EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-small-cell lung cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Neoplasms
• Hodgkin Lymphoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Transitional Cell Carcinoma
• Urologic Neoplasms

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Status: Authorised. Therapeutic area: Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms. MAH: Merck Sharp & Dohme B.V.. Decision date: 19/06/2026